NeuroKaire is a precision psychiatry company developing a functional, brain-relevant platform that predicts individual antidepressant response by measuring drug-induced neuroplasticity in patient-derived neurons. By quantifying how a patient’s own neurons structurally and synaptically respond to specific antidepressants, NeuroKaire enables true within-patient drug selection, significantly outperforming existing pharmacogenetic and clinical prediction models and reducing trial-and-error prescribing.